NSCLC patients with high FATS expression had a lower tumour progression or longer overall survival time than those with low FATS expression (24.5% vs. 56.7%, 67 months vs. 41 months; P = 0.001), as revealed by the Kaplan–Meier analysis (Fig. 1e). The gene discussed is C10orf90; the disease is neoplasm.